Literature DB >> 35273734

Pars plana vitrectomy assisted by intravitreal injection of conbercept enhances the therapeutic effect and quality of life in patients with severe proliferative diabetic retinopathy.

Qin Wang1, Hui Cai2, Dahua Xu3, Lin Cui1, Yan Zhang4, Mei Chen1.   

Abstract

OBJECTIVE: To explore the application value of intravitreal injection of Conbercept (IVC)-assisted pars plana vitrectomy (PPV) in patients with severe proliferative diabetic retinopathy (PDR).
METHODS: Forty-eight patients with severe PDR who underwent surgical treatment in Chongqing Aier Eye Hospital between October 2019 and June 2021 were retrospectively enrolled, and their clinical data were analyzed. Of them, 22 patients receiving PPV alone were assigned to the PPV group, and the remaining 26 patients treated with IVC-assisted PPV were included in the PPV+IVC group. The intra-operative indicators, postoperative complication rate, visual acuity (VA) improvement, and postoperative quality of life (QoL) were compared between the two groups. The levels of vascular endothelial growth factor (VEGF), placental growth factor (PIGF), and basic fibroblast growth factor (bFGF) in aqueous humor (AH) as well as serum contents of interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) were determined by Enzyme Linked Immunosorbent Assay (ELISA).
RESULTS: Compared to the PPV group, the operation time of the PPV+IVC group was significantly shorter, and the incidence of severe intraoperative blood loss (IBL), bipolar electrocoagulation hemostasis, iatrogenic retinal breaks (IRBs), postoperative silicone oil tamponade (SOT), and overall complications were significantly reduced. After surgery, the central macular thickness (CMT) was lower and the best corrected visual acuity (BCVA) assessed by the standard visual acuity chart and VA were significantly more improved in the PPV+IVC group versus the PPV group. After the use of Conbercept, the AH levels of VEGF, PIGF, and bFGF in the PPV+IVC group decreased and were significantly lower than those in the PPV group. The PPV+IVC group also showed lower serum levels of TNF-α, IL-6, and IL-1β than the PPV group.
CONCLUSIONS: IVC-assisted PPV can effectively reduce the difficulty of surgical treatment for PDR, better improve the postoperative VA of patients, and reduce inflammation with fewer complications. AJTR
Copyright © 2022.

Entities:  

Keywords:  Conbercept; VEGF; pars plana vitrectomy; proliferative diabetic retinopathy

Year:  2022        PMID: 35273734      PMCID: PMC8902581     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  26 in total

1.  Nitric oxide and TNF-α are correlates of diabetic retinopathy independent of hs-CRP and HbA1c.

Authors:  Pegah Khaloo; Reihane Qahremani; Soghra Rabizadeh; Mohammad Omidi; Armin Rajab; Firouzeh Heidari; Ghasem Farahmand; Masoume Bitaraf; Hossein Mirmiranpour; Alireza Esteghamati; Manouchehr Nakhjavani
Journal:  Endocrine       Date:  2020-06-03       Impact factor: 3.633

Review 2.  Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.

Authors:  Jonathan M Smith; David Hw Steel
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

3.  Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy.

Authors:  Sergio E Hernández-Da Mota; Silvia M Nuñez-Solorio
Journal:  Eur J Ophthalmol       Date:  2010 Nov-Dec       Impact factor: 2.597

4.  Pars Plana Vitrectomy for Full-Thickness Macular Holes in Patients with Proliferative Diabetic Retinopathy and Active Fibrovascular Proliferation.

Authors:  Mushfig Karimov; Lala Akhundova; Tarlan Aliyeva
Journal:  Clin Ophthalmol       Date:  2020-12-01

5.  Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications.

Authors:  A P Schachat; R T Oyakawa; R G Michels; T A Rice
Journal:  Ophthalmology       Date:  1983-05       Impact factor: 12.079

6.  Assessment of Neurotrophins and Inflammatory Mediators in Vitreous of Patients With Diabetic Retinopathy.

Authors:  Joseph D Boss; Pawan Kumar Singh; Hemang K Pandya; Joaquin Tosi; Chaesik Kim; Asheesh Tewari; Mark S Juzych; Gary W Abrams; Ashok Kumar
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-10-01       Impact factor: 4.799

7.  Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy.

Authors:  Jian Guan; Na Cai; Li-Min Liu; Ning Zhao; Ning-Ning Liu
Journal:  Diabetes Ther       Date:  2020-04-30       Impact factor: 2.945

8.  Concentrations of VEGF and PlGF Decrease in Eyes After Intravitreal Conbercept Injection.

Authors:  Jun Zhou; Zheng Liu; Meng Chen; Zhi-Heng Luo; Yun-Qiu Li; Guang-Ying Qi; Tao Liu
Journal:  Diabetes Ther       Date:  2018-10-30       Impact factor: 2.945

Review 9.  Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis.

Authors:  Xiaolei Sun; Jingjing Zhang; Jingyi Tian; Shijiu Chen; Fanxing Zeng; Gongqiang Yuan
Journal:  J Ophthalmol       Date:  2020-03-23       Impact factor: 1.909

10.  MicroRNA-15b Targets VEGF and Inhibits Angiogenesis in Proliferative Diabetic Retinopathy.

Authors:  Ying Yang; Yan Liu; Yiping Li; Zhongli Chen; Yixin Xiong; Taicheng Zhou; Wenyu Tao; Fan Xu; Hanling Yang; Seppo Ylä-Herttuala; Shyam S Chaurasia; Whaley-Connell Adam; Ke Yang
Journal:  J Clin Endocrinol Metab       Date:  2020-11-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.